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ABSTRACT 
Background: Despite the evidence as to the benefits of Vitamin A supplementation (VAS) among children 6-59 
months of age, the feasibility of introduction and potential benefit of vitamin A supplementation in the neonatal 
period in public health programs are uncertain.  
Objective: The  primary objective was to evalauate the  feasibility and effectiveness of early neonatal Vitamin A 
supplementation (single dose of 50,000 international units delivered within 48-72 hours after birth) delivered 
through the public sector Lady Health Worker (LHW) in rural Pakistan and to document its association with 
reduction of mortality at 6 months of age. 
Methods: A community-based, cluster randomized, placebo-controlled trial was undertaken in two districts of 
rural Pakistan. LHWs dispensed Vitamin A/placebo in identical capsules to newborns within 48-72 hours of birth. 
Follow up visits were undertaken at 1 week of age and thereafter every 4 weeks until 6 months of age. 
Results: Of a total 15,433 consecutive pregnancies among eligible women of reproductive age, 13,225 
pregnancies were registered, 12,218 live births identified and 11,028 newborns reached by LHWs.  Of these 
5380 (49%) received neonatal Vitamin A Supplementation and 5648 (51%) placebo. The LHWs successfully 
delivered the capsules to 79% of newborns within 72 hours of birth with no significant adverse effects. Although 
the proportion of days observed with symptoms of fever, diarrhea or rapid breathing were lower with neonatal 
VAS, these differences were not statistically significant. Mortality rates in the two groups were at 6 months of 
age . 
 
Conclusions: While our study demonstrated that neonatal VAS was safe and could be feasibly delivered by 
LHWs in Pakistan as part of their early post-natal visits, the overall lack of benefit on neonatal and 6 months 
morbidity and mortality in our population suggests the need for further evaluation of this intervention in 
populations at risk.  
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INTRODUCTION 
Globally 6.3 million children die each year before reaching their fifth birthday and almost 44% of these deaths 
occur during the first 28 days of life (1). Annually 2.9 million neonatal deaths are reported globally that are 
largely preventable (2, 3). Maternal and childhood undernutrition contributes to almost 45% of child deaths and 
the association of vitamin A deficiency with excess risk of child morbidity and mortality after 6 months of age is 
well recognized. (4) Vitamin A supplementation is recommended as a key lifesaving intervention for children 
aged 6 to 59 months in populations at risk for vitamin A deficiency (5). Given widespread maternal vitamin A 
deficiency in some regions and the fact that a large proportion of child deaths occur among young infants, it is 
plausible that alleviation of vitamin A deficiency among young infants could be beneficial. Although some 
studies have reported a beneficial impact on the infant mortality in south Asia and among populations with 
relatively high prevalence of maternal vitamin A deficiency (6, 7) other recent studies have shown modest 
benefits (8).These findings cannot be generalized to the global context as other randomized controlled trials in 
similar settings have not shown any benefits (9-12).  
 Pakistan has relatively high neonatal and under-5 child mortality rates compared with other South Asian 
countries (13) and persistent high burden of maternal and child vitamin A deficiency at the population level (14). 
In 1994 the Government of Pakistan launched a national program for family planning and primary care, the so-
called the Lady Health Worker (LHW) program with the objective of improving health and access to essential 
primary health care to rural and selected peri-urban communities. The LHWs are community-based health 
workers with secondary education, who are trained and employed by the Ministry of Health to deliver these 
services (15).  Each LHW is responsible for a population of around 1000. The LHWs register all pregnant women 
(pregnancies) in their catchment area and as part of their assignments are supposed to undertake a postnatal 
visit at household level within 72 hours of birth, although the overall coverage of this intervention is very low 
(16). LHWs are supervised by lady health supervisors (LHS) employed at a Basic Health Unit (BHU). Each LHS is 
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typically responsible for 20-25 LHWs in her catchment area and supervise their overall work and monthly 
progress reports. The program is operational throughout the country and currently employs over 100,000 LHWs. 
In June 2011 as part of a constitutional amendment, the LHW program was devolved to the provinces.  The 
national Lady Health Workers (LHW) program is the mainstay of much of primary care preventive interventions 
in rural settings and while a number of newborn interventions have been piloted through this program (17-19), 
there are none that have evaluated the feasibility and effectiveness of an early post-natal visit and provision of a 
vitamin A supplement.  
We undertook a community-based placebo controlled cluster-randomized trial in rural Pakistan to evaluate the 
feasibility of delivering early neonatal vitamin A administration (single dose 50,000 international unit or 
placebo) through LHWs and its potential impact on health outcomes and mortality at 6 months of age. The trial 
is registered with Clinical Trials.gov (NCT00674089) and approved by the Ethics committees at the Aga Khan 
University and the National Bioethics Committee of the Government of Pakistan.  
II. METHODS 
CONTEXT AND POPULATION 
The trial was conducted between January, 2007 and October 2010 in two rural districts, Sukkur and Jhelum, in 
Pakistan, representing a typical mix of periurban and rural, multiethnic populations of 1,108,000 and 1,048,000 
respectively.  The intervention was developed and implemented in partnership with the LHW program and the 
study areas selected on the basis of demographic patterns, and population mix, number of functional LHWs and 
approval by the LHW program for partnership and data sharing.  
The LHWs and LHSs underwent three days separate training at the beginning of the project. The training focused 
on understanding the program objectives for commodity delivery, appropriate storage (light protection) for the 
capsules, transport and administration of capsules, recognition and reporting of adverse events, morbidities and 
hospitalizations. The LHWs were trained to record morbidities reported by mothers covering the two weeks 
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prior to the visit and to examine the newborn/infant for relevant morbidities using the standard WHO/IMCI 
algorithms for classification of respiratory tract infections, sepsis and diarrhea.  Refresher trainings (1 day) were 
provided during the course of the study on quarterly basis. 
STUDY DESIGN, CLUSTER DEFINITION, SAMPLE SIZE ESTIMATION AND ALLOCATION 
A baseline census of the study areas in both districts was undertaken to enumerate households, collect socio-
economic and demographic data and determine LHW density. Study clusters were defined as the catchment 
population of one LHW, usually an average population of 1000 covering 100 to 150 households. An external 
consultant generated the computerized allocation sequence of clusters to each intervention group using Epi Info 
3.5.3 with restricted randomization based on population size, expected births and LHW presence.  
Given the reported rural infant mortality rates from the PDHS (2006) (20), in the two districts of about 80 per 
thousand live births, and a projected 25% reduction in mortality at 6 months of age, we estimated that 400 
clusters (200 in each group, averaging 30 births per cluster annually) would be required to demonstrate this 
impact with 80% power and 5% significance (21).  
STUDY PROCEDURES & DATA COLLECTION 
Pregnant women were registered by LHWs as part of their regular activities and standard operating procedures. 
Families were encouraged to report a birth as soon as it occurred and LHWs also liaised with the local traditional 
birth attendants to identify births. The LHWs were encouraged to visit the birth household ( within 72 hours) 
following  notification of  birth to obtain written informed consent, collect information on the mother and 
newborn, and to administer a single dose of oral vitamin A (50,000 IU) or placebo to the baby. The LHW also 
counseled the mother on basic preventive measures and encouraged her to breastfeed the newborn 
immediately after capsule administration to ensure consumption of the entire dose. All live born infants within 
participating villages were potentially eligible for inclusion in the study. Infants with obvious congenital 
malformations and birth weight less than 1500 g, were excluded. No vitamin A doses were administered in 
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facilities and for facility births the LHW visited the household at least once within 72 hours of birth and if the 
mother and infant pair had returned from the hospital, she administered the neonatal dose. 
The LHW returned empty Vitamin A capsules to the LHS who kept an inventory of the repository and provided 
supervision, capsule replenishment and monitored the LHWs activities as per routine. The LHW repeated the 
home visits on days 7 and 28 and thereafter at monthly intervals until 6 months of age. On the first follow up 
visit at day 7 (unless passively reported earlier by the family) the LHW collected information on any adverse 
events reported by the mother after vitamin A administration, and thereafter information was collected on 
neonatal illnesses, care seeking, hospitalizations and any deaths at the monthly visits. At each visit the infant’s 
vital status was evaluated, signs of illness recorded, if any, and action taken as per LHW program policies.  
Blood samples from a randomly selected subset of 450 infants were obtained at 6 months of age and analyzed 
for serum retinol concentration. The samples were collected at household level by trained phlebotomists, 
separated and frozen in the field and transported to the Nutrition Research lab at the Aga Khan University for 
analysis using standard methods (22).    
MASKING, DISTRIBUTION OF CAPSULES AND QUALITY CONTROL 
The vitamin A capsule contained (50,000 units) of retinol palmitate in soybean oil and the placebo contained 
Vitamin E (10 IU) in soybean oil. The capsules were identical in appearance (Banner Pharmacaps, Alberta, 
Canada) and supplied in bulk through the courtesy of the Micronutrient Initiative (Ottawa, Canada). The 
capsules were stored at the AKU Pharmacy with close temperature regulation and light protection, and supplied 
to the districts in similar containers with unique codes representing clusters and specific LHWs. The content and 
allocation of the capsules were masked from the investigators and field staff and the container codes were only 
known to the external consultant responsible for cluster randomization and the chair of the Data Safety and 
Monitoring Board (DSMB). The containers (Vit A and placebo) were covered with aluminum foil and transported 
at room temperature to the field at monthly intervals based on requirement and consumption. Research 
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supervisors carried out random check of Vit A stores to ensure compliance. Strict fidelity of allocation of vitamin 
A (or placebo) containers by LHWs was maintained by the AKU Pharmacy.  
DATA CAPTURE, TRIAL SAFETY MONITORING AND ANALYSIS 
Twelve independent teams of data collectors (each with six members including a supervisor) conducted a cross-
sectional household survey of the entire catchment population at baseline and thereafter at three monthly 
intervals. The data collectors were provided with 3 days training on data collection instruments and 
communication skills. These teams collected information on live births, deaths, migrations and also obtained 
information on causes of deaths through verbal autopsies.  They obtained information on receipt of Vit A by 
newborns from mothers/family elders.  Additionally a separate data collection team visited the household at 
fortnightly interval to gather data on morbidity and collected details of diarrheal episodes, respiratory problems 
and febrile episodes that the neonate /infant encountered during the preceding 2 weeks.  
The primary outcome was all-cause mortality by six months of age Secondary outcomes were common 
morbidities (febrile illness, diarrhea or pneumonia). Infant deaths were identified at home visits by LHWs and 
also verified through independent data collector team of all recruited children. In case of discrepancy between 
LHW record and independent study data collectors, the study supervisor verified deaths through household 
visits.  Cause of death was determined from an independent review of verbal autopsies by two pediatricians. 
Disagreements were referred to a third assessor experienced in verbal autopsies.  
All data files were double entered in MS Fox pro and analyzed using  STATA version 12 in addition to mortality 
outcomes at 6 months of ageand morbidity data were analyzed . The proportion of monthly  visits at which a 
child was reported to have had morbidity was compared between the two arms using Generalized estimating 
equation (GEE), account for clusters, controlling for the month of the visit (as a proxy for age).  
The trial was overseen by a DSMB consisting of four members with expertise in cluster randomized trials, 
newborn and child health, and medical statistics, was constituted. The DSMB had access to allocation codes and 
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undertook blinded safety analyses to check for any excess in mortality or severe morbidity outcomes. The DSMB 
met thrice during the course of the study to assess progress, adverse events and key outcomes. The Chair of the 
DSMB gave permission to unmask the study after completion of the trial, data locking and analysis of primary 
outcomes. While data on primary outcomes were available by November 2011, given the LHW program 
devolution to the provinces in mid-2011, permission to share the results from the concerned LHW programs in 
Sindh and Punjab took considerably longer, and was finally received in April 2013.  
RESULTS 
The cross sectional surveys identified 15,433 pregnant women in the catchment area during the course of the 
study, of which the LHWs registered a total of 13,225 pregnant women (86%). Assessment of gestational age 
was based on the maternal recall of her last menstrual period. Birth outcomes were recorded for 12,218 women 
(92%) while 1007 (8%) were lost to follow-up and a further 374 (3.1%) pregnancies ended in stillbirths. The 
remaining pregnancies resulted in 11,918 live born babies. Of these, 171 live born babies (1.4%) died before the 
LHW conducted the first post natal visit, with the majority of the neonatal deaths (66.3% in placebo and 52.9% 
in neonatal Vitamin A Supplementation group) occurring within the first 24 hours of life. A further 609 (5.1 %) 
neonates were excluded for other reasons (Figure 1). Altogether 11,028 (92.5%) of all live born newborns were 
randomized to receive either placebo or neonatal Vitamin A Supplementation capsules, of which 10,286 (86.3%) 
infants were followed up until death or 6 months of age. 
The baseline characteristics of the two study arms were comparable (Table 1). Study participants in both the 
groups were also comparable with respect to timing of interventions, gender and BCG vaccination status. 
Overall, majority of the deliveries, 55.2% occurred at home, mostly attended by TBAs. Among the newborns that 
had their weights assessed at birth, mean recorded birth weights were 2.82 kg in the placebo arm and 2.81 kg in 
neonatal Vitamin A Supplementation arm. Overall 8.3% of infants were low birth weight (< 2.5 kg) in placebo 
arm compared with and 9.3% in neonatal Vitamin A Supplementation. (Table 2). Newborn in the community 
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receive first dose of polio and BCG at the BHUs by government employed vaccinators and the BCG vaccination 
status for the two groups was comparable.  
The LHWs successfully delivered the capsules to the majority (80%) of newborns (neonatal Vitamin A 
Supplementation /placebo) within 72 hours of birth, of them 60% received these within 24 hours. A total of 26 
adverse events were documented in the both the groups, neonatal Vitamin A Supplementation 10, placebo 16 
(p=0.19). Of the ten adverse events in the neonatal Vitamin A Supplementation group, seven were diarrheal 
episodes. Only one case of bulging fontanel was reported in each group (Table 3). 
We did not measure maternal or neonatal serum retinol concentrations at birth or recruitment. However, 
among the subset of 449 infants sampled at 6 months of age, there was no evidence of a difference in mean 
serum retinol concentrations between the two groups (Table 4). However, the proportion of severe retinol 
deficiency was significantly lower among supplemented infants.  
There were no differences in reported morbidities between the two arms of the study. The morbidity rates of 
diarrheal episodes, fever and rapid breathing and severe pneumonia were similar in both groups (Table 5). 
Neonatal deaths (0-28days) per protocol were comparable in both the placebo and intervention arms (48 vs 57 
p value 0.59). Similarly no difference was documented in (0-6 months) mortality also (115 vs 128 p value 
0.64).The Intention to treat analysis (ITT)) also revealed similar results (Table 6).   
DISCUSSION  
Our findings show that it was feasible for LHWs in Pakistan to deliver vitamin A supplements to newborn infants 
within 72 hours of birth.  Given the importance attached to postnatal visits (23) in terms of impact on newborn 
survival, this is an important step in developing integrated packages for preventive care after birth. The 
repertoire of interventions that can be implemented in the immediate postnatal period and the first few days of 
life e.g. cord chlorhexidine application (19), breastfeeding promotion and oral polio, BCG and hepatitis B 
vaccines, the addition of neonatal vitamin A dosing to these interventions is both feasible and potentially cost-
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effective. The LHWs and families did not report any significant adverse effects with the 50,000 unit dosing. Only 
one case was reported to have bulging fontanel, which self-resolved within 72 hours, while another case of 
vomiting and suspected seizures was found to be well at examination and resolved within 24 hours. These data 
suggest that overall neonatal Vitamin A Supplementation is a safe intervention that can be administered by 
CHWs in community settings.  
The key question is if the intervention is effective with health and survival benefits. We did not find any impact 
on mortality at 6 months of age and the observed effects on morbidity were also marginal and non-significant. 
Several limitations must be recognized in our study. Our trial was designed to assess the feasibility and 
effectiveness in a large rural district but had a smaller sample size than other similar studies (7). We did not 
measure vitamin A status in mothers or newborns at baseline and hence it is difficult to ascertain the extent to 
which biochemical vitamin A deficiency was widespread in the target population .. However, a recent national 
nutrition survey including these very districts has highlighted vitamin A deficiency on serum retinol estimation at 
42.5% and 54% among women of reproductive age and children under 5 from this district respectively (14). 
Similar burden  has been documented in Africa with Vitamn A deficiency as high as 43% with higher prevalence 
in the rural population,Others  have demonstrated somewhat lower levels . (24, 25)  
Our findings of the lack of significant benefit of neonatal vitamin A supplementation on survival at 6 months of 
age is at variance with other studies in South Asia (6, 7, 8). However, other studies in Africa have failed to show 
any benefits of neonatal vitamin A supplementation on survival (10, 26). Although some reviews have failed to 
show any mortality benefit of neonatal vitamin A dosing (27), our previous assessment of the evidence 
suggested geographic variation in response to neonatal vitamin A supplementation which could relate to 
prevalent maternal vitamin A or multiple micronutrient deficiencies (28, 29). Although some gender related 
differences in outcomes and survival have been reported (30), we did not find any differences in outcomes 
among female infants. Previous studies of neonatal vitamin A supplementation have also reported mixed results 
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on morbidity patterns. In Indonesia, neonatal vitamin A supplementation was associated with reduced number 
of clinic visits (29). Our data on morbidity patterns also did not show any reduction in morbidity rates or 
hospitalizations with neonatal vitamin A supplementation.  
Breast-feeding provides protection against vitamin A deficiency even in populations where deficiency may be 
endemic. Our study population had almost universal breast feeding (98%) in both the placebo and 
supplemented arms. The lack of apparent benefit on mortality may also be because of protection from vitamin 
A deficiency conferred by exclusive breast-feeding early in life. The blood samples at 6 month of age did show 
an impact on the proportion with severe vitamin A deficiency among the supplemented infants.  
 
Conclusion: 
We conclude that the delivery and distribution of Vit A was feasible through the public sector LHWs. However 
recommendations as to its inclusion in the repertoire of interventions must await further evidence of benefits 
and risks. Our study did not show any benefit on infant survival Two of three large trials evaluating impact of 
vitamin A on infant mortality have been published recently, demonstrating no benefits (10, 26), although the 
study in India was associated with a 10% reduction in mortality at six months of age (8), once again lending 
support to the contention that the intervention may be relevant in populations with varying rates of maternal 
nutritional risks and vitamin A deficiency. Further recommendations on neonatal vitamin A supplementation 
must therefore await additional contextual analysis and targeting to populations at greatest risk, as well as 
comparison with alternative strategies (29, 32).  
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Table 1: Socio-demographic of the infant’s families pre-randomization (Baseline survey), n (%) 
 
          
  Characteristic Placebo  (n=25474) VAS (n=28431)   
  Married women aged 15–49 years 23877 26076   
  Median age (IQR) in years 30 (25 - 40) 31 (26 - 40)   
  Maternal literacy  6623 (28%) 7544 (29%)   
  Household density 6.2 6.1   
  Monthly household income 
  
  
  ≤ 6000 PKR 16437/25033 (67%) 18814/28260 (68%)   
  > 6000 PKR 8227/25033 (33%) 9028/28260 (32%)   
  Median (IQR) 5000  (3000 - 8000) 5000 (3000 - 7000)   
  Nature of construction of household 
  
  
  Pucca (concrete) 14289/25431 (56%) 12015/28390 (42%)   
  Semi-pucca 5063/25431 (20%) 11251/28390 (40%)   
  Katcha 5623/25431 (22%) 4774/28390 (17%)   
  Others 456/25431 (2%) 350/28390 (1%)   
  Living rooms in the house 
  
  
  One 8800/25191 (35%) 8699/28272 (31%)   
  Two or more 16365/25191 (65%) 19561/28272 (69%)   
  Main cooking fuel 
  
  
  Electricity 3279/25474 (13%) 3742/28431 (13%)   
  Natural Gas 4829/25474 (19%) 3590/28431 (13%)   
  Firewood 17094/25474 (67%) 20764/28431 (73%)   
  Others 216/25474 (1%) 289/28431 (1%)   
  Household with electricity 24470/25425(96%) 27816/28399(98%)   
  Main drinking water source 
  
  
  Well/ Hand pump 4552/25429 (18%) 4826/28387 (17%)   
  Communal tap/Motor pump 14978/25429 (59%) 17032/28387 (60%)   
  Others 5900/25429 (23%) 6529/28387 (23%)   
  Type of latrine 
  
  
  Open fields 9133/25427 (36%) 9918/28385 (35%)   
  Pit latrine 3983/25427 (16%) 4449/28385 (16%)   
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  WC connected to public sewerage / open drains 12253/25427 (48%) 13970/28385 (49%)   
  
   
  
  Data are n, n (%) or median (IQR)       
  N.B. Denominator can be varied due to not reported responses     
          
 
 
 
 
 
 
 
 
Table 2: Baseline characteristics of mothers and Delivery and Newborn Care Practices (post randomization) 
 
          
  Characteristic Placebo VAS    
  Baseline characteristics of mothers (n=5962) (n=6256)   
  ANC visits during current pregnancy 
  
  
  Never 474/5693 (8%) 551/5947 (9%)   
  1-3 2658/5693 (47%) 2608/5947 (44%)   
  > 3 2561/5693 (45%) 2788/5947 (47%)   
  Iron or multivitamin supplementation during current pregnancy 
 
  
  Yes 4342/5962 (73%) 4579/6256 (73%)   
  Addiction during the pregnancy period 
  
  
  Tobacco 64(1%) 52(1%)   
  Non-smoking tobaccoǂ 182(3%) 143(2%)   
  Reproductive history 
  
  
  Gravida Mean (SD) 2.51 (2.57) 2.49 (2.78)   
  Delivery and Newborn Care Practices (n=5380) (n=5648)   
  Place of delivery 
  
  
  At home 2892/5341 (54%) 3169/5632 (56%)   
  Govt. Health facility 715/5341 (13%) 838/5632 (15%)   
  Private Hospital 930/5341 (17%) 908/5632 (16%)   
  Private clinic 804/5341 (15%) 717/5632 (13%)   
  Delivery attended 
  
  
  Skilled provider* 2779/5346 (52%) 2800/5628 (50%)   
  Unskilled 339/5346 (48%) 2828/5628 (50%)   
  Use of Clean Delivery Kits 3508/5291(66%) 3604/5420 (67%)   
  Gender of the child  
  
  
  Male 2772/5378 (52%) 2965/5645 (53%)   
  Female 2606/5378 (49%) 2680/5645 (48%)   
  Birth weight (kg)  
  
  
  < 2.5  306/3693(8.%) 331/3549(9%)   
  ≥2.5 3387/3693 (92%) 3218/3549 (91%)   
  Birth weight Mean (SD) kg 2.82 (0.72) 2.81 (0.74)   
  BCG given to newborn after birth 
  
  
  Yes 1614/5370 (30%) 1629/5630 (29%)   
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  Data are n, n (%), or mean (SD), ǂpan, niswar & gutka, * Doctor , Nurse  & LHV   
  N.B. Denominator can be varied due to not reported responses   
          
 
 
 
 
 
 
 
 
 
 
 
 
Table 3: Adverse events following Vitamin A supplementation, n (%) 
          
    Placebo  VAS  p-value 
          
  
Adverse event reported within one week of 
supplementation 
16/5380 (0.3%) 10/5648 (0.2%) 
0.2 
(95%CI 0.2-0.5) (95%CI 0.1-0.3) 
  Distribution of Adverse Event 
   
  Loose Motion 
8/16(50%) 7/10 (75%) 
 (95%CI 23-77) (95%CI 39-100) 
  Vomiting 
2/16 (12.5%) 1/10 (10.0%) 
 (95%CI 0-30) (95%CI 0-31) 
  Bulging fontanel 
1/16 (6%) 1/10 (10%) 
 (95%CI 0-19) (95%CI 0-31) 
  Unconsciousness 
1/16 (6%) 0/10 (0%) 
 (95%CI 0-19) (95%CI - -) 
  Seizures 
1/16 (6%) 1/10 (10%) 
 (95%CI 0-19) (95%CI 0-31) 
  Fever 
3/16 (19%) 0/10 (0%) 
 (95%CI 0-40) (95%CI - -) 
  Hospitalization during first 6 months of life 
185/5380 (3.4%) 185/5648 (3.3%) 
0.6 
(95%CI 2.9-3.9) (95%CI 2.8-3.7) 
  Data are n, n (%)       
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Table 4: Serum Retinol level at 6 months of age 
            
    Placebo (n=219) VAS (n=230) p-value   
            
  Retinol  (µg/dl)         
  Severe deficiency (<10 µg/dL) 
19/219 (9%) 79/230 (4%) 
0.04   
(95%CI 5-12) (95%CI 1-6) 
  Deficiency (<20 µg/dL) 
82/219 (37%) 79/230 (34%) 
0.5   
(95%CI 31-44) (95%CI 28-41) 
  Mean (SE) 
25.7 (0.87) 26.9 (0.99) 
0.4   
(95%CI 24-28) (95%CI 25-29) 
  Median (QR) 23.7 (16.4, 33.3) 23.7 (16.8, 32.8) 
 
  
  Data are n, n (%), or mean (SE) or median (IQR)   
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Table 5: Reported morbidities by treatment arm  
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    Placebo  VAS  
Odds ratio1 
  
(VAS versus Placebo) (95% CI) 
  Proportion of monthly visits at which child was reported to have been ill in preceding 30 days 
 
  
  Number of monthly visits completed  26571 27465 
 
  
  Fever 8130/26571 (31%) 7928/27465 (29%) 0.94 (0.76, 1.16)) P=0.5   
  Diarrhoea 2,609/26571 (10%) 2,272/27465 (8%) 0.78 (0.57, 1.08) P=0.1   
  Rapid breathing 740/26571 (2.8%) 617 /27465 (2.3%) 0.92 (0.55, 1.53) P=0.7   
  Severe Pneumonia2 245/26571 (0.9%) 121/27465 (0.4%) 0.42 (0.16, 1.11) P=0.1   
  1: Odds ratio estimated using Generalized estimating equation (GEE) to account for the cluster randomisation and adjusted for month of visit   
  Data are n, n (%), or mean proportion of days with illness         
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Table 6: Effect of vitamin A post supplementation on primary outcome: overall and stratified by sex 
 
Mortality (post supplementation) 
  
  
Number of newborns supplemented Risk per 1,000 live births Odds Ratio 
p- 
value  
Effect size 
(95% CI)   
Placebo VAS 
Placebo VAS (95% CI)  
Events 
No. of 
newborns 
Events 
No. of 
newborns 
a. Neonatal Mortality (0-28 days)                   
Overall 48 5380 57 5648 
9 
(95%CI 7-12) 
10 
(95%CI 8-13) 
1.13 
 (0.76, 1.66) 
0.6 0.06 (-0.14, 0.28) 
Male 21 2774 26 2966 
7.6 
(95%CI 5-12) 
8.8 
(95%CI 6-13) 
1.15  
(0.65, 2.06) 
0.6 0.08 (-0.23, 0.39) 
Female 27 2606 31 2682 
10.4 
(95%CI 7-15) 
11.6 
(95%CI 8-16) 
1.11  
(0.66, 1.87) 
0.7 0.06 (-0.22, 0.34) 
b. Mortality (0 - 6 months)                   
Overall 115 5380 128 5648 
21  
(95%CI 18-26) 
23 
(95%CI 19-27) 
1.06 
 (0.82, 1.37) 
0.6 0.03 (-0.10, 0.17) 
Male 49 2774 58 2966 
17.7 
(95%CI 13-23) 
19.6 
(95%CI 15-25) 
1.10  
(0.75, 1.62) 
0.6 0.05 (-0.15, 0.26) 
Female 66 2606 70 2682 
25.3 
(95%CI 20-32) 
26.1 
(95%CI 21-33) 
1.03  
(0.73, 1.44) 
0.9 0.01 (-0.17, 0.20) 
Mortality (pre and post supplementation)                 
c. Neonatal Mortality (0-28 days)                   
Overall 134 5706 142 5970 
23 
(95%CI 20-28) 
24 
(95%CI 20-28) 
1.01 
 (0.80, 1.27) 
0.9 0.007 (-0.12. 0.13) 
Male 73 2959 75 3145 
25 
(95%CI 20-31) 
24 
(95%CI 19-30) 
0.96 
 (0.69, 1.33) 
0.8 -0.01 (-0.19, 0.16) 
Female 61 2747 67 2825 
22.2 
(95%CI 17-28) 
23.7 
(95%CI 19-30) 
1.06  
(0.75, 1.52) 
0.7 0.03 (-0.15, 0.23) 
d. Mortality (0 - 6 months)                   
Overall 201 5706 213 5970 
35 
(95%CI 31-40) 
36 
(95%CI 31-41) 
1.03 
 (0.83, 1.23) 
0.9 0.007 (-0.10, 0.11) 
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Male 101 2959 107 3145 
34 
(95%CI 28-41) 
34 
(95%CI 28-41) 
0.99 
 (0.75, 1.31) 
1.0 -0.002 (-0.15, 0.15) 
Female 100 2747 106 2825 
36 
(95%CI 30-44) 
38 
(95%CI 31-45) 
1.03 
 (0.78, 1.36) 
0.8 0.01 (-0.13,0.17) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
